Restricted accessResearch articleFirst published online 2019-10
Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2′- O -Methoxyethyl Antisense Oligonucleotide
Although antisense oligonucleotides (ASOs) are well tolerated preclinically and in the clinic, some sequences of ASOs can trigger an inflammatory response leading to B cell and macrophage activation in rodents. This prompted our investigation into the contribution of genetic architecture to the ASO-mediated inflammatory response. Genome-wide association (GWA) and transcriptomic analysis in a hybrid mouse diversity panel (HMDP) were used to identify and validate novel genes involved in the acute and delayed inflammatory response to a single 75 mg/kg dose of an inflammatory 2′-O-methoxyethyl (2′MOE) modified ASO. The acute response was measured 6 h after ASO administration, via evaluation for increased plasma production of interleukin 6 (IL6), IL10, monocyte chemoattractant protein 1 (MCP-1) and macrophage inflammatory protein-1β (MIP-1β). Delayed inflammation was evaluated by spleen weight increases after 96 h. We identified single nucleotide polymorphisms (SNPs) on chromosomes 16 and 17 associated with plasma MIP-1β, IL6, and MCP-1 levels, and one on chromosome 8 associated with increases in spleen weight. Systems genetic analysis utilizing transcriptomic data from HMDP strain macrophages determined that the acute inflammatory SNPs were expression quantitative trait locis (eQTLs) for CCAAT/enhancer-binding protein beta (Cebpb) and salt inducible kinase 1 (Sik1). The delayed inflammatory SNP was an eQTL for Rho guanine nucleotide exchange factor 10 (Arhgef10). In vitro assays in mouse primary cells and human cell lines have confirmed the HMDP finding that lower Sik1 expression increases the acute inflammatory response. Our results demonstrate the utility of using mouse GWA study (GWAS) and the HMDP for detecting genes modulating the inflammatory response to pro-inflammatory ASOs in a pharmacological setting.
Get full access to this article
View all access options for this article.
References
1.
RaalFJ, SantosRD, BlomDJ, MaraisAD, CharngMJ, CromwellWC, LachmannRH, GaudetD, TanJL, et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 375:998–1006.
2.
JaschinskiF, RothhammerT, JachimczakP, SeitzC, SchneiderA and SchlingensiepenKH. (2011). The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2. Curr Pharm Biotechnol, 12:2203–2213.
3.
Al-AsaaedS and WinquistE. (2013). Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer. Curr Oncol Rep, 15:113–118.
4.
JanssenHL, ReesinkHW, LawitzEJ, ZeuzemS, Rodriguez-TorresM, PatelK, van der MeerAJ, PatickAK, ChenA, et al. (2013). Treatment of HCV infection by targeting microRNA. N Engl J Med, 368:1685–1694.
5.
JonesNR, PeguesMA, McCroryMA, SingletonW, BethuneC, BakerBF, NorrisDA, CrookeRM, GrahamMJ and Szalai.AJ (2012). A selective inhibitor of human C-reactive protein translation is efficacious in vitro and in C-reactive protein transgenic mice and humans. Mol Ther Nucleic Acids, 1:e52.
6.
HuaY, SahashiK, RigoF, HungG, HorevG, BennettCF and KrainerAR. (2011). Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature, 478:123–126.
7.
KordasiewiczHB, StanekLM, WancewiczEV, MazurC, McAlonisMM, PytelKA, ArtatesJW, WeissA, ChengSH, et al. (2012). Sustained therapeutic reversal of huntington's disease by transient repression of huntingtin synthesis. Neuron, 74:1031–1044.
LeeRG, CrosbyJ, BakerBF, GrahamMJ and CrookeRM. (2013). Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res, 6:969–980.
10.
KriegAM. (1996). An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med, 128:128–133.
11.
MonteithDK, HenrySP, HowardRB, FlournoyS, LevinAA, BennettCF and CrookeST. (1997). Immune stimulation—a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des, 12:421–432.
12.
RobertsTL, SweetMJ, HumeDA and StaceyKJ. (2005). Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol, 174:605–608.
13.
BurelSA, MachemerT, RagoneFL, KatoH, CauntayP, GreenleeS, SalimA, GaardeWA, HungG, et al. (2012). Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response. J Pharmacol Exp Ther, 342:150–162.
KawaiT and AkiraS. (2010). The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol, 11:373–384.
19.
KawaiT and AkiraS. (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 34:637–650.
20.
KriegAM, YiAK, MatsonS, WaldschmidtTJ, BishopGA, TeasdaleR, KoretzkyGA and KlinmanDM. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374:546–549.
21.
BauerS, KirschningCJ, HackerH, RedeckeV, HausmannS, AkiraS, WagnerH and LipfordGB. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A, 98:9237–9242.
22.
BlasiusAL and BeutlerB. (2010). Intracellular toll-like receptors. Immunity, 32:305–315.
23.
SiroisCM, JinT, MillerAL, BerthelootD, NakamuraH, HorvathGL, MianA, JiangJ, SchrumJ, et al. (2013). Rage is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med, 210:2447–2463.
24.
PazS, HsiaoJ, CauntayP, SorianoA, BaiL, MachemerT, XiaoX, GuoS, HungG, et al. (2017). The distinct and cooperative roles of toll-like receptor 9 and receptor for advanced glycation end products in modulating in vivo inflammatory responses to select CpG and non-CpG oligonucleotides. Nucleic Acid Ther, 27:272–284.
25.
SennJJ, BurelS and HenrySP. (2005). Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther, 314:972–979.
26.
GhazalpourA, RauCD, FarberCR, BennettBJ, OrozcoLD, van NasA, PanC, AllayeeH, BeavenSW, et al. (2012). Hybrid mouse diversity panel: a panel of inbred mouse strains suitable for analysis of complex genetic traits. Mamm Genome, 23:680–692.
27.
BennettBJ, FarberCR, OrozcoL, KangHM, GhazalpourA, SiemersN, NeubauerM, NeuhausI, YordanovaR, et al. (2010). A high-resolution association mapping panel for the dissection of complex traits in mice. Genome Res, 20:281–290.
28.
RauCD, ParksB, WangY, EskinE, SimecekP, ChurchillGA and LusisAJ. (2015). High-density genotypes of inbred mouse strains: improved power and precision of association mapping. G3 (Bethesda), 5:2021–2026.
29.
HuiST, ParksBW, OrgE, NorheimF, CheN, PanC, CastellaniLW, CharugundlaS, DirksDL, et al. (2015). The genetic architecture of NAFLD among inbred strains of mice. Elife, 4:e05607.
30.
FarberCR, BennettBJ, OrozcoL, ZouW, LiraA, KostemE, KangHM, FurlotteN, BerberyanA, et al. (2011). Mouse genome-wide association and systems genetics identify Asxl2 as a regulator of bone mineral density and osteoclastogenesis. PLoS Genet, 7:e1002038.
31.
ParksBW, SallamT, MehrabianM, PsychogiosN, HuiST, NorheimF, CastellaniLW, RauCD, PanC, et al. (2015). Genetic architecture of insulin resistance in the mouse. Cell Metab, 21:334–346.
32.
RauCD, WangJ, AvetisyanR, RomayMC, MartinL, RenS, WangY, and Lusis. (2015). Mapping genetic contributions to cardiac pathology induced by beta-adrenergic stimulation in mice. Circ Cardiovasc Genet, 8:40–49.
33.
WattsLM, ManchemVP, LeedomTA, RivardAL, McKayRA, BaoD, NeroladakisT, MoniaBP, BodenmillerDM, et al. (2005). Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes, 54:1846–1853.
34.
SallamT, JonesM, ThomasBJ, WuX, GillilandT, QianK, EskinA, CaseroD, ZhangZ, et al. (2018). Transcriptional regulation of macrophage cholesterol efflux and atherogenesis by a long noncoding RNA. Nat Med, 24:304–312.
35.
MatsushitaT, AshikawaK, YonemotoK, HirakawaY, HataJ, AmitaniH, DoiY, NinomiyaT, KitazonoT, et al. (2010). Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke. Hum Mol Genet, 19:1137–1146.
36.
TsukadaJ, YoshidaY, KominatoY and AuronPE. (2011). The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine, 54:6–19.
37.
SundbergTB, ChoiHG, SongJH, RussellCN, HussainMM, GrahamDB, KhorB, GagnonJ, O'ConnellDJ, et al. (2014). Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc Natl Acad Sci U S A, 111:12468–12473.
38.
HirataM, KugimiyaF, FukaiA, OhbaS, KawamuraN, OgasawaraT, KawasakiY, SaitoT, YanoF, et al. (2009). C/EBPbeta promotes transition from proliferation to hypertrophic differentiation of chondrocytes through transactivation of p57. PLoS One, 4:e4543.
39.
ZhangZ, BryanJL, DeLassusE, ChangLW, LiaoW and SandellLJ. (2010). CCAAT/enhancer-binding protein β and NF-κB mediate high level expression of chemokine genes CCL3 and CCL4 by human chondrocytes in response to IL-1β. J Biol Chem, 285:33092–33103.
40.
QuC and QuY. (2017). Down-regulation of salt-inducible kinase 1 (SIK1) is mediated by RNF2 in hepatocarcinogenesis. Oncotarget, 8:3144–3155.
41.
YoonYS, SeoWY, LeeMW, KimST and KooSH. (2009). Salt-inducible kinase regulates hepatic lipogenesis by controlling SREBP-1c phosphorylation. J Biol Chem, 284:10446–10452.
42.
NixonM, Stewart-FitzgibbonR, FuJ, AkhmedovD, RajendranK, Mendoza-RodriguezMG, Rivera-MolinaYA, GibsonM, BerglundED, JusticeNJ and BerdeauxR. (2016). Skeletal muscle salt inducible kinase 1 promotes insulin resistance in obesity. Mol Metab, 5:34–46.
WeinMN, ForetzM, FisherDE, XavierRJ and KronenbergHM. (2018). Salt-inducible kinases: physiology, regulation by camp, and therapeutic potential. Trends Endocrinol Metab, 29:723–735.
45.
ClarkK, MacKenzieKF, PetkeviciusK, KristariyantoY, ZhangJ, ChoiHG, PeggieM, PlaterL, PedrioliPG, et al. (2012). Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A, 109:16986–16991.
46.
ZhangY, GaoW, YangK, TaoH and YangH. (2018). Salt-inducible kinase 1 (SIK1) is induced by alcohol and suppresses microglia inflammation via NF-κB signaling. Cell Physiol Biochem, 47:1411–1421.
47.
SanosakaM, FujimotoM, OhkawaraT, NagatakeT, ItohY, KagawaM, KumagaiA, FuchinoH, KunisawaJ, NakaT and TakemoriH. (2015). Salt-inducible kinase 3 deficiency exacerbates lipopolysaccharide-induced endotoxin shock accompanied by increased levels of pro-inflammatory molecules in mice. Immunology, 145:268–278.
48.
RossmanKL, DerCJ and SondekJ. (2005). GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol, 6:167–180.
49.
PirieE, RayS, PanC, FuW, PowersAF, PolikoffD, MillerCM, KudrnaKM, HarrisEN, et al. (2018). Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting malat1. PLoS Genet, 14:e1007732.
50.
LoirandG, ScalbertE, BrilA and PacaudP. (2008). Rho exchange factors in the cardiovascular system. Curr Opin Pharmacol, 8:174–180.
51.
MongPY and WangQ. (2009). Activation of Rho kinase isoforms in lung endothelial cells during inflammation. J Immunol, 182:2385–2394.
52.
WangC, SongS, ZhangY, GeY, FangX, HuangT, DuJ and Gao.J (2015). Inhibition of the Rho/Rho kinase pathway prevents lipopolysaccharide-induced hyperalgesia and the release of TNF-alpha and IL-1beta in the mouse spinal cord. Sci Rep, 5:14553.
53.
VemulaS, ShiJ, MaliRS, MaP, LiuY, HannemanP, KoehlerKR, HashinoE, WeiL and KapurR. (2012). Rock1 functions as a critical regulator of stress erythropoiesis and survival by regulating p53. Blood, 120:2868–2878.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
